Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 randomized blinded study of aprocitentan in resistant hypertension
MOH_2020-05-18_008954Phase 3Not yet recruiting
- Sponsor
- Idorsia
- Start
- May 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of aprocitentan in resistant hypertension (RH) (3 arms), sponsored by Idorsia. Primary endpoint: Blood pressure lowering effect of aprocitentan added to standard therapy. Planned start May 2020; status: not yet recruiting.
02
Drugs
aprocitentan
03
Conditions
resistant hypertension (RH)
Beyond the preview
Go deeper on MOH_2020-05-18_008954.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2020-05-18_008954.